13 July 2021 in Expert Review of Anti-infective Therapy
Introduction: Dengue virus is a global health threat, with approximately 390 million dengue infections annually. Efficient vaccines for dengue prevention are currently lacking. This review aims to summarize the current progress in dengue vaccine development. Area covered: This article discusses recent dengue vaccine developments based on the published literature and ClinicalTrials.gov website up to December 2020. Expert opinion: The first live-attenuated chimeric yellow-fever/tetravalent dengue vaccine (CYD-TDV), Dengvaxia, has been licensed in several countries. However, the low efficacy of this vaccine was observed in children and dengue-naïve individuals. It also increased the risk of severe dengue in people who had not been exposed to dengue. The heterologous prime-boost regimen of sequential immunization with DENVax and Dengvaxia covers four serotypes of immunogenicity, eliminating the effect of ADE. Moreover, a heterologous prime-boost regimen that combines inactivated vaccines with alum and live attenuated vaccines might increase the immunogenic response. The lack of an ideal animal model is an obstacle to the development of dengue vaccines, and the macaque model may be considered for similar immunologic responses in humans.
27 July 2022 in Emerging Microbes & Infections
Candida auris, a multidrug resistant pathogenic yeast, has spread worldwide and caused several outbreaks in healthcare settings. Here, we report the first case of C. auris candidemia in Taiwan in a patient with a two month history of hospitalization in Vietnam. We performed further investigation on the isolate from the present case as well as the previously reported C. auris isolate identified from a wound in 2018 in Taiwan, which was the first case reported in Taiwan. Both C. auris isolates were found to be susceptible to fluconazole, amphotericin B, and echinocandins. Additionally, mutations in ERG11 or FKS1 were not detected in either isolate. Microsatellite genotyping revealed that both isolates belonged to the South Asian clade. In recent years, C. auris has emerged as a global concern, and differences in clades and susceptibility patterns mandate further awareness and systematic surveillance.
24 August 2024 in Journal of Microbiology, Immunology and Infection
Vancomycin-variable enterococci (VVE) are vanA-carrying Enterococcus faecium that are phenotypically susceptible to vancomycin and can only be detected using molecular methods, leading to the possibility of treatment failure and posing threats to infection control. This study aimed to determine the prevalence of VVE and its associated clinical risk factors. This retrospective study was conducted in two hospitals in southern Taiwan. Patients with phenotypically vancomycin-susceptible E. faecium bacteremia were enrolled between 2017 and 2021. VVEs were defined as isolates harboring the vanA gene that were phenotypically susceptible to vancomycin. Vancomycin-susceptible E. faecium (VSE) isolates were phenotypically susceptible to vancomycin and lacked vanA or vanB genes. Of the 142 enrolled patients, 121 (85.2%) had VSE and 21 (14.8%) had VVE. Resistance rates to penicillin, tetracycline, and fosfomycin were higher in VVE isolates. Malignancy (adjusted odds ratio [aOR] = 4.87; 95% confidence interval [CI] 1.54-15.41, p = 0.007) and central venous catheter usage (aOR = 4.69; 95% CI 1.49-14.78, p = 0.008) were the independent risk factors associated with VVE bacteremia. Being male (aOR = 0.12, CI 0.03-0.44, p = 0.002) was less likely to be associated with VVE bacteremia. Although VVE was not associated with 30-day mortality (38.1% [VVE] vs. 35.5% [VSE], p = 0.822), one case of subsequent vancomycin-resistant enterococci infection in the VVE group with vancomycin treatment (4.8%, 1/21) was identified, which led to subsequent mortality. The prevalence of VVE was high among E. faecium isolates with vancomycin-susceptible phenotypes in southern Taiwan. Although the current study revealed that VVE bacteremia was not associated with poor clinical outcome, further multicenter surveillance survey is recommended to evaluate the possible impact of VVE on public health in Taiwan.
17 October 2026 in Clinical Infectious Diseases
29 July 2022 in Clinical Infectious Diseases
14 September 2026 in Journal of Microbiology, Immunology and Infection
Dengue is a mosquito-borne disease that caused a large outbreak in Taiwan in 2023. Some published studies about this outbreak suggest higher disease severity while we observed the opposite epidemiological trend in the southern part of Taiwan. Therefore, we conducted comparative analysis for clinical manifestation and disease severity between two outbreak periods. We retrospectively analyzed 4009 cases diagnosed at one medical center and two regional hospitals in Taiwan, including 3588 cases from 2014 to 2015 and 421 cases from 2023. Moderate-to-severe dengue was defined as dengue with warning signs or severe dengue by World Health Organization (WHO) definitions. The factors associated with dengue severity were assessed by multivariate logistic regression. The proportion of moderate-to-severe dengue was significantly lower in 2023 (P < 0.001), even after adjusting for covariates (adjusted odds ratio 0.259, P < 0.001). In 2023, patients were generally less symptomatic and exhibited fewer warning signs, particularly mucosal bleeding. Compared with the 2014-2015 outbreak, the 2023 outbreak was characterized by a lower white blood cell nadir, platelet nadir occurring 1 day later (7 vs. 6 days after symptom onset), and aspartate aminotransferase (AST) levels peaking 3 days later. In conclusion, manifestations of dengue patients during the 2023 outbreak in southern Taiwan might be less severe, compatible with our clinical observation. The different clinical and laboratory features in 2023 included a lower frequency of warning signs-particularly mucosal bleeding-as well as a platelet nadir occurring 1 day later, and serum AST levels peaking 3 days later. These findings suggest that dengue manifestations differ between outbreak periods in Taiwan and may reform patient management during future outbreaks. Further research is warranted to verify these findings and to elucidate the underlying mechanisms.